Physician profile
John Keith Abbott
NPI 1255540936
$2,705.79
in general payments reported to CMS, 2019-2025
32 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $323 · 2022: $555 · 2023: $422 · 2024: $1,285 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232 · Travel and Lodging: $596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,231.67 |
| Travel and Lodging | $595.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $550.92 | 2024 | Phasix Mesh |
| Davol INC. | $494.53 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $308.04 | 2022-2025 | Entyvio, Ninlaro |
| Astrazeneca Pharmaceuticals LP | $134.02 | 2021-2023 | Lynparza |
| Janssen Biotech, INC. | $115.27 | 2021-2024 | Stelara, Simponi, Remicade |
| Phathom Pharmaceuticals, INC. | $102.43 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $98.74 | 2022-2024 | Retevmo |
| Regeneron Healthcare Solutions, INC. | $89.21 | 2023 | Dupixent, Libtayo |
| Acera Surgical, INC. | $68.59 | 2022 | |
| Incyte Corporation | $65.39 | 2022-2025 | Jakafi |
| Amgen INC. | $62.99 | 2021-2023 | Amjevita, Avsola |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.15 | 2022-2024 | Trulance |
| Medtronic, INC. | $54.54 | 2021-2023 | Ligasure, Signia |
| Daiichi Sankyo INC. | $46.70 | 2024-2025 | Enhertu |
| Seagen INC. | $46.53 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $44.28 | 2024 | Pyrukynd |
| Sun Pharmaceutical Industries INC. | $42.40 | 2022-2024 | |
| Puma Biotechnology, INC. | $38.58 | 2021 | |
| Tersera Therapeutics LLC | $30.95 | 2023 | Zoladex |
| Merck Sharp & Dohme LLC | $30.36 | 2022-2024 | Keytruda |
| Novartis Pharmaceuticals Corporation | $30.31 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $25.70 | 2021-2022 | |
| Morphosys, US INC. | $24.22 | 2023 | Monjuvi |
| Abbott Laboratories | $21.32 | 2021 | |
| Foundation Medicine, INC. | $17.34 | 2021 | |
| Aimmune Therapeutics, INC. | $16.49 | 2024 | |
| Aveo Pharmaceuticals, INC. | $15.69 | 2022 | |
| Ardelyx, INC. | $15.08 | 2025 | Ibsrela |
| Pacira Pharmaceuticals Incorporated | $14.99 | 2023 | Exparel |
| Nestle Healthcare Nutrition INC. | $14.79 | 2022 | |
| Genentech USA, INC. | $14.71 | 2024 | Lunsumio, Polivy, Columvi |
| Eisai INC. | $14.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.